ALAB: who owns it, and who’s predicted to buy next
Astera Labs Inc · Information Technology · on the Prior Moves forward board for 2026-09-30 at rank #69. Research, not investment advice.
Predicted to buy next quarter
3 tracked investors are included in the model-ranked expectations for ALAB in 2026-09-30. This is a forecast about a later filing, not a confirmation that anyone has bought the security or a recommendation to do so.
- Lee Ainslie · Maverick
- Chuck Akre · Akre Capital
- Brad Gerstner · Altimeter
Strongest ranked investor signal: Daniel Loeb. No calibrated purchase probability is shown.
Currently disclosed holders
From the most recent 13F books we track, 3 investors disclose a position in ALAB (weight = share of that investor’s US equity book). A 13F can be up to 45 days stale.
| Investor | Book weight |
|---|---|
| Light Street | 6.7% |
| Whale Rock | 6.1% |
| Lee Ainslie · Maverick | 4.5% |
Mutual fund and ETF holders
321 US mutual funds and ETFs from 167 fund families reported a position in ALAB for the quarter ending 2026-06-30. Against their own report a quarter earlier, 93 raised shares, 115 opened a new position, 77 cut and 17 sold out. Source: SEC Form N-PORT, which funds file about 60 days after quarter end. Share counts, not trades: a change can reflect fund inflows rather than a decision about ALAB.
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Vanguard Index Funds | 8 | 36.0% |
| Ishares Trust | 11 | 16.1% |
| Invesco Qqq Trust, Series 1 | 1 | 10.4% |
| Vaneck Etf Trust | 3 | 5.9% |
| Fidelity Contrafund | 4 | 2.2% |
| Jpmorgan Trust Ii | 1 | 1.9% |
| Smallcap World Fund Inc | 1 | 1.7% |
| Capitol Series Trust | 1 | 1.6% |
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.
See the full ranked board on top picks, how the PriorScore is built on how it works, the honest edge numbers on methodology, and the running accuracy on the prediction leaderboard. Forward quarter 2026-09-30, data as of 2026-10-16. Research, not investment advice, see the disclaimer.